DOI:

Emergency and prophylactic use of miniaturised veno-arterial extracorporeal membrane oxygenation (vaECMO) in transcatheter aortic valve implantation (TAVI)

Husser O.1, Holzamer A.2, Philipp A.2, Schmid C.2, Riegger G.1, Hengstenberg C.1, Hilker M.2

Pot-pourri

Emergency and prophylactic use of miniaturised veno-arterial extracorporeal membrane oxygenation (vaECMO) in transcatheter aortic valve implantation (TAVI)

Aims: In transcatheter aortic valve implantation (TAVI) short-term mortality closely relates to life-threatening procedural complications. Veno-arterial extracorporeal membrane oxygenation (vaECMO) can be used to stabilise the patient in emergency situations. However, for the prophylactic use of vaECMO in very-high-risk patients undergoing TAVI there is no experience. We report our centre’s experience using vaECMO in TAVI.

Methods and results: From January 2009 to August 2011, we performed 131 TAVI. Emergency vaECMO was required in eight cases (7%), due to ventricular perforation (n=3), haemodynamic instability/cardiogenic shock (n=4) and haemodynamic deterioration due to ventricular tachycardia (n=1). From August 2011 onwards, prophylactic vaECMO was systematically used in very-high-risk patients (n=9, 11%) during 83 procedures and emergency vaECMO in one case (1%) due to ventricular perforation. Median logistic EuroSCORE in prophylactic vaECMO patients was considerably higher compared to the remaining TAVI population (30% vs. 15%, p=0.0003) while in patients with emergency vaECMO it was comparable (18% vs. 15%, p=0.08). Comparing prophylactic to emergency vaECMO, procedural success, procedural-related death, and 30-day mortality were 100% vs. 78% (p=0.5), 0% vs. 33% (p=0.2) and 0% vs. 44% (p=0.08), respectively. Major vascular complications and rate of life-threatening bleeding did not differ in both groups (11% vs. 11%, p=0.99 and 11% vs. 33%, p=0.6) and were not vaECMO-related.

Conclusions: Life-threatening complications during TAVI can be managed using emergency vaECMO but mortality remains high. Systematic use of prophylactic vaECMO in very-high-risk patients is safe and might be advocated in selected high-risk patients.

Volume 8 Supplement Q
Sep 30, 2012
Volume 8 Supplement Q
View full issue


Key metrics

Suggested by Cory

Clinical research

10.4244/EIJ-D-19-00797 Feb 7, 2020
Feasibility and safety of transcaval transcatheter aortic valve implantation: a multicentre European registry
Costa G et al
free

10.4244/EIJV7I5A99 Sep 30, 2011
Complications of transcatheter aortic valve implantation: avoidance and management
Hildick-Smith D et al
free

Research Correspondence

10.4244/EIJ-D-23-01046 Apr 15, 2024
Feasibility and safety of transcaval venoarterial extracorporeal membrane oxygenation in severe cardiogenic shock
Giustino G et al
Trending articles
151.43

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
55.9

Clinical research

10.4244/EIJ-D-22-00621 Feb 20, 2023
Long-term changes in coronary physiology after aortic valve replacement
Sabbah M et al
free
54.9

Expert review

10.4244/EIJ-D-21-01010 Jun 24, 2022
Device-related thrombus following left atrial appendage occlusion
Simard T et al
free
43.75

Clinical Research

10.4244/EIJ-D-21-01091 Aug 5, 2022
Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study
Medranda G et al
free
39.95

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved